ARDX

Healthcare Biotechnology

Ardelyx, Inc.

$3.34

-0.09 -2.62% today

Price History

Not enough data

Key Stats

Market Cap

862.35M

Avg Volume

4.04M

EPS

-$0.23

52W High

$8.40

52W Low

$3.29

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

11.16

P/B Ratio

5.59

P/S Ratio

1.91

EV/EBITDA

-25.94

EV/Revenue

1.85

Margins

Gross Margin 75.0%

Operating Margin (10.3%)

Net Margin (12.4%)

EBITDA Margin (7.1%)

Growth & Returns

Revenue Growth (YoY)

23.8%

Return on Equity

(38.6%)

Return on Assets

(4.3%)

Liquidity & Leverage

Current Ratio

3.34

Quick Ratio

2.89

Debt / Equity

1.90

Total Cash

281.83M

Total Debt

282.51M

About

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.